Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample

https://doi.org/10.1016/j.drugalcdep.2021.108512Get rights and content

Highlights

  • Only 40 % of AI/ANs in specialty OUD care receive medication treatments.

  • Only 22 % of specialty treatment facilities serving AI/ANs offer opioid agonists.

  • AI/ANs access medications in specialty care at similar rates as other race groups.

  • AI/ANs in opioid treatment have higher rates of methamphetamine co-use.

  • AI/ANs in the South or justice-referred are least likely to receive medications.

Abstract

Background

American Indians and Alaska Natives (AI/ANs) are disproportionately affected by the opioid overdose crisis. Treatment with medications for opioid use disorder (MOUD) can significantly reduce overdose risk, but no national studies to date have reported on the extent to which AI/ANs access these treatments overall and in relation to other groups.

Methods

The current study used two national databases - the 2018 National Survey on Substance Abuse Treatment Services and the 2017 Treatment Episode Dataset - to estimate the extent to which MOUD is available and used among AI/ANs across the U.S.

Results

We found that facilities serving AI/ANs (N = 1,532) offered some MOUD at similar rates as other facilities (N = 13,277) (39.6 vs. 40.6 %, p = 0.435) but were less likely to offer the standard of care with buprenorphine or methadone maintenance (22.4 % vs. 27.6 %, p < 0.001). AI/AN clients in specialty treatment (N = 8,136) exhibited slightly higher MOUD use (40.0 % vs. 38.6 %, p = 0.009) relative to other race groups (N = 673,938). AI/AN clients were also more likely to exhibit greater prescription opioid use and methamphetamine co-use relative to other groups. AI/AN clients in the South (aOR:0.23[95 %CI: 0.19−0.28] or referred by criminal justice sources (aOR:0.13[95 %CI: 0.11−0.16] were least likely to receive MOUD.

Conclusions

We conclude that most AI/ANs in specialty treatment do not receive medications for opioid use disorder, and that rates of MOUD use are similar to those of other race groups. Efforts to expand MOUD among AI/ANs that are localized and cater to unique characteristics of this population are gravely needed.

Introduction

Over the past two decades, American Indians and Alaska Natives (AI/ANs) have experienced a fivefold increase in opioid overdose deaths (Tipps et al., 2018), a faster growth rate than the national average. AI/ANs continue to have the highest rate of prescription opioid misuse and overdoses, and rising deaths involving heroin, synthetic opioids, and stimulants(Kariisa et al., 2019; Scholl et al., 2019; Substance Abuse and Mental Health Administation, 2018). AI/ANs often use alcohol and other drugs at higher rates, begin using substances at earlier ages(Whitesell et al., 2012) and have elevated rates of chronic disease and mental health conditions that exacerbate addiction risk (Barnes et al., 2010; Skewes and Blume, 2019). Still, this group has received little attention in national discussions of the opioid epidemic and in research and public health responses to address it.

One essential opioid response strategy is expanding access to medications for opioid use disorder (MOUD) - especially the agonist medications methadone and buprenorphine - which effectively reduce overdose and other opioid-related harms(Leshner and Mancher, 2019; Sordo et al., 2017). Expanding MOUD has also been a focus of overdose prevention efforts within AI/AN communities, through initiatives such as the federally-funded Tribal Opioid Response Grants and other tribe-initiated and government programs(Tipps et al., 2018; Venner et al., 2018; Zeledon et al., 2019). Unfortunately, regulatory hurdles and stigma against medications have made access to MOUD a challenge nationwide (Leshner and Dzau, 2019). Efforts to expand MOUD treatment in AI/AN communities have also encountered unique barriers such as limited resources of tribe and Indian Health Service (IHS)-run behavioral health services, a lack of trained providers near reservations, and the perception that medication treatments are incongruent with traditional values and healing practices (Rieckmann et al., 2017; Tipps et al., 2018; Venner et al., 2018; Zeledon et al., 2019). Given AI/ANs already have low rates of treatment for substance use compared to other groups (Substance Abuse and Mental Health Administation, 2018), MOUD-specific barriers only exacerbate the gap in receipt of effective care.

Despite recognition of a need to expand MOUD access in behavioral health settings, the extent to which MOUD are currently available and used among AI/ANs seeking OUD treatment is not well-documented. One study surveyed 192 substance use treatment programs that serve AI/ANs, and found that only 28 % offered MOUD (Rieckmann et al., 2017). More information is needed about how MOUD among AI/ANs compares to other race groups, and the settings where the largest gaps remain. Additionally, more information is needed about individual, clinical, and structural factors impacting MOUD use among this group. This study aims to fill some of these gaps by using publicly-available data to characterize the landscape of MOUD treatment availability and utilization among AI/ANs across the U.S. We do this by exploring the extent to which MOUD are offered in substance use treatment facilities that explicitly serve AN clients compared to other facilities, and then assessing use of MOUD among AI/AN clients admitted to specialty treatment for OUD relative to clients of other races. We hypothesized that AI/ANs would have lower access to MOUD at the facility and client level.

Section snippets

Data

We used two databases operated by the Substance Abuse and Mental Health Services Administration (SAMHSA). The first is the 2018 National Survey on Substance Abuse Treatment Services (N-SSATS), an annual census of characteristics of public and private substance use treatment facilities in the U.S., including information on types of medications offered (Batts et al., 2014). In 2018, the N-SSATS collected information from 14,809 treatment facilities, with a response rate of 94.8 % among invited

Availability of MOUD across treatment facilities

Of the 14,809 facilities that were surveyed in N-SSATS in 2018, 1,532 (10.3 %) explicitly served AI/AN clients. Of these, the majority (1,470) accepted IHS funds as a source of payment, 262 were operated directly by tribal governments, 81 had staff that spoke Native languages, and 23 were operated by the IHS. Table 1 displays the proportion of facilities within each of these categories that 1) offered any MOUD for any purpose, or 2) offered agonist maintenance with methadone or buprenorphine.

Discussion

To our knowledge, this is the first study to examine MOUD use among American Indians and Alaska Natives in a national sample. While some literature has compared MOUD utilization across racial/ethnic groups, studies often exclude AI/ANs because of their relatively small representation in the general population or due to insufficient information on race/ethnicity (Hansen et al., 2016; Krawczyk et al., 2017a; Lagisetty et al., 2019). Our findings suggest that, similar to other racial/ethnic groups

Conclusions

MOUD are critical for addressing the opioid epidemic, and yet they continue to be underutilized across the U.S.(Leshner and Mancher, 2019). This study shows that AI/AN populations are no exception to this trend, and that this group experiences overall low uptake of MOUD with vast variation in access across different regions of the U.S. AI/ANs experience similar or even somewhat greater use of MOUD relative to other race groups, but may be less likely to use MOUD for maintenance rather than

Role of Funding Source

This Study was funded by a Bloomberg Philantropies grant.

Contributors

NK conducted the analyses and drafted the manuscript; BG, EAS and BS helped conceptualize the studyand EAS and BS oversaw the overall project; NJA, EP and KS significantly revised and helped frame the manuscript in the context of the literature.

Availability of data and material

Data used for this study is publicly available from the Substance Abuse and Mental Health Services Administration

Code availability

Not Applicable

Declaration of Competing Interest

No conflict declared.

Acknowledgments

This work was funded by a grant from Bloomberg Philanthropies. Authors would like to thank colleagues at Bloomberg Philanthropies, Vital Strategies, Pew Charitable Trusts, CDC Foundation, and Johns Hopkins Bloomberg School of Public health for their valuable contributions to and review of this work.

References (35)

  • B.P. Jarvis et al.

    Extended-release injectable naltrexone for opioid use disorder: a systematic review

    Addiction

    (2018)
  • C.M. Jones et al.

    Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–2017

    Addiction

    (2019)
  • M. Kariisa et al.

    Drug overdose deaths involving cocaine and psychostimulants with abuse potential — United States, 2003–2017

    MMWR Morb. Mortal. Wkly. Rep.

    (2019)
  • H.D. Kleber

    Pharmacologic treatments for opioid dependence: detoxification and maintenance options

    Dialogues Clin. Neurosci.

    (2007)
  • N. Krawczyk et al.

    Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine

    Health Aff. (Millwood)

    (2017)
  • P.A. Lagisetty et al.

    Buprenorphine treatment divide by race/ethnicity and payment

    JAMA Psychiatry

    (2019)
  • M.R. Larochelle et al.

    Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study

    Ann. Intern. Med.

    (2018)
  • Cited by (15)

    • Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic

      2022, Journal of Substance Abuse Treatment
      Citation Excerpt :

      A feasibility study evaluated virtual cognitive behavioral therapy for SUD in the Black church and found high uptake of the intervention, retention, and reduced substance use (Williams et al., 2006). Culturally centered treatment models may increase treatment uptake and retention with Indigenous people by utilizing existing community networks and trust, taking a holistic view of health, and having a culturally specific design that incorporates a focus on family and community wellness (D'Amico et al., 2021; Krawczyk et al., 2021; Lillie et al., 2021). In addition, getting out of the brick-and-mortar clinic to deliver low-threshold SUD care in community-based, faith-based, or mobile outreach models may address barriers to access and treatment uptake among minoritized populations (Chan et al., 2021; Hall et al., 2014; Hanson et al., 2015; Moraes et al., 2010).

    • Comparing the feasibility of four web-based recruitment strategies to evaluate the treatment preferences of rural and urban adults who misuse non-prescribed opioids

      2021, Preventive Medicine
      Citation Excerpt :

      Since 1999, rates of drug overdose mortality rose disproportionally among America Indian and Alaska Native populations (Joshi et al., 2018). Because facilities predominately serving American Indian or Alaska Native populations are less likely to offer buprenorphine or methadone (Krawczyk et al., 2021), using culturally tailored implementation strategies to enhance access to all MOUD treatment options may be particularly important (Venner et al., 2018). Limitations to this cross-sectional survey include recruitment of a convenience sample and reliance on self-reported data.

    • Quantifying opioid use disorder Cascade of Care outcomes in an American Indian tribal nation in Minnesota

      2021, Drug and Alcohol Dependence
      Citation Excerpt :

      For example, standardized implementation of programs that offer MOUD often lack an explicit integration of spirituality and culture that honor spirituality, holistic healing, and wellness (Legha et al., 2014). In 2017, only 22 % of American Indian and Alaskan Native-serving substance use treatment facilities in the US offered opioid agonist treatment and in 2018 only 40 % of American Indian and Alaskan Native individuals in specialty OUD treatment in the US received MOUD (Krawczyk et al., 2021). This cautious reception toward MOUD in many American Indian populations may be due in part to the perceived lack of fit with staff expertise and training, stigma toward substance use and treatment, and misperceptions about MOUD (Venner et al., 2018).

    View all citing articles on Scopus
    View full text